Abstract
NeoRx in pancreatic cancer (PCa) holds promise in improving resectability and avoiding unnecessary surgery in pts with occult metastases. NeoRx has been shown to produce encouraging 5-yr survival rates in patients (pts) who complete treatment while delaying surgery for 3-4 months (Evans, JCO 2008). However, plastic stent occlusions with cholangitis occurred in a high proportion of cases. To improve stent patency, avoid early complications of migration, and ensure no interference with the resection line, we chose to study the impact of using short non-foreshortening uncoated self-expanding metal biliary stents (SSEMS) pre-operatively in PCa cases recommended to undergo NeoRx.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
